Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of ...

Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.

Trace3 announces another strategic evolution toward a 'services-first' model, marked by significant investments in capabilities that unite strategic consulting with advanced technology delivery. The ...

Wolters Kluwer, a global leader in professional information, software solutions, and services, has released compelling survey findings on the adoption and investment intentions for Artificial ...

These scientists sought to answer a simple question. They ended up stumbling upon a discovery that could pave the way for a ...

Hopkins research: Delta-8 less potent but has similar misuse potential as ... Protein-based vaccines have been used for years ...

As confirmed measles cases continue to rise in the southern U.S., Canada, and Lower Michigan, the percentage of local ...

Hopkins research: Delta-8 less potent but has similar misuse ... have been used for years to prevent other diseases including hepatitis B and shingles. Each year, the three manufacturers update ...

Gilead acquired Livdelzi – an oral PPAR delta agonist – as the main asset ... diseases" from established drugs such as its viral hepatitis franchise. The FDA has granted accelerated approval ...

Measles cases are on the increase, nationwide and in Colorado. Lisa Young talks to Mary Cable from Delta Health Hospital and ...

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion FOSTER CITY, Calif.--(BUSINESS WIRE)--#Earnings--Gilead Sciences, ...